

## Thermo Fisher introduces Heracell incubators to support future of fully automated labs

12 June 2024 | News

### First-of-its-kind innovation for CO<sub>2</sub> Incubators delivers new features compatible with lab automation



To support the future implementation of workflow automation in cell therapy production, Thermo Fisher Scientific has introduced the Thermo Scientific™ Heracell™ VIOS™ 250i AxD CO<sub>2</sub> Incubators.

These first-of-their-kind CO<sub>2</sub> incubators are designed for integration into automated and modular laboratories. The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk. Now adding the innovation of patent-pending automated door control, the Heracell VIOS AxD CO<sub>2</sub> incubator opens automatically when integrated into a centralized lab automation platform, allowing vessel loading and unloading through robotic control and supporting continuous cell therapy production processes.

Emerging cell therapy manufacturers, biotech and pharmaceutical companies focused on bringing advanced therapies to market want to automate production of cultured cells without compromising quality. The new innovative design of the Heracell VIOS Incubator modernises cell therapy production without compromising on contamination control features.

The Heracell VIOS 250i AxD CO<sub>2</sub> incubators are the most advanced incubators in the VIOS portfolio. Owing to its excellent cell culturing conditions that help ensure critical quality attributes of cells, Heracell VIOS 250i AxD CO<sub>2</sub> incubators support the emerging automated cell therapy production processes on a large scale, culminating in an advancement that helps improve human health by supporting the cell manufacturing process within cell and gene therapies.